Please login to the form below
dermatitis
This page shows the latest dermatitis news and features for those working in and with pharma, biotech and healthcare.
Sanofi extends growth spurt thanks to Genzyme, Dupixent
atopic dermatitis drug Dupixent providing the acceleration in its Q4 results.
Latest news
-
As France protests, Sanofi takes axe to 670 jobs
dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.
-
Orphan drugs from Biogen and Amicus win UK Prix Galien
Sanofi’s treatment for moderate-to-severe atopic dermatitis Dupixent was highly commended in the same category.
-
Dupixent helps put Sanofi back on growth track
and delivered on its promise thanks to a surge in sales for atopic dermatitis drug Dupixent.
-
New data keeps AbbVie’s star pipeline therapies on track
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Upadacitinib is already in a phase III trial in atopic dermatitis and picked up a
-
Gilead, Galapagos JAK inhibitor clears phase II test
Like filgotinib, upadacitinib is also being tested in a string of other indications, including psoriatic arthritis, Crohn’s disease, ulcerative colitis and atopic dermatitis.
More from news
Approximately 9 fully matching, plus 57 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,
-
Leo has its eyes on the prize
Psoriasis and dermatitis may seem the same in everybody but maybe the picture is more like it is in cancer where you have subsets. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across Europe while psoriasis levels show no signs of
-
Pharma deals continue to slide
Phase II MAb to block IL-13 for treatment of atopic dermatitis.
-
Deal Watch September 2016
as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.
-
Deal Watch July 2016
AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Dr Desiree Luthman joins Verona Pharma
atopic dermatitis in the US.
-
Ziarco appoints Mike Grey to board of directors
Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report
Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
-
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report
Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
-
Atopic Dermatitis — Going Beyond the Pill
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
-
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
-
Research Partnership
Atopic Dermatitis — Going Beyond the Pill.
More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Health Consultant - Brand Comms
-
Competitive Salary
-
Digital Account Director
-
Salary TBC
- Scientific Director – Medical Communications
-
Salary TBC
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Senior Account Manager, Medical Communications, London
-
Excellent package
Subscribe to our email news alerts
- Fishawack acquires Dudnyk
- GSK’s myeloma drug hits target, prompting rapid filing pledge
- Winners of the HSJ Partnership Awards 2019 unveiled
- 50 questions for delivering an exceptional healthcare brand experience
- Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity
- The brand strategy revolution
PMHub
Hayward Medical Communications
Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
